SONOMA PHARMACEUTICALS INC (SNOA)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$1.33+0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SNOA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 24 industry peers · Company calendar date is not available
SNOA — debt issuance
Dated 2026-06-18
Other Events. As previously reported, on September 26, 2025, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Agreement”), with Ladenburg Thalmann & Co. Inc. (“Ladenburg”), pursuant to which the Company may offer and sell, from time to time, through Ladenburg, as agent, shares of its common stock, $0.0001 par value per share. Sales of shares of common stock under the Agreement are made pursuant to the registration statement on Form S-3 (Fil…
Why it matters: Growth in Microcyn sales is key to the company's expansion strategy. It reflects market acceptance.
Supportive ifRevenue from Microcyn sales goes up from last quarter.
Worry ifRevenue from Microcyn sales goes down or stays the same.
Why it matters: Better operating income means the company is controlling costs. This can help investors feel good.
Supportive ifOperating income improves from -$40,000 in Q1 2027 to positive in Q2 2027.
Worry ifOperating income stays negative or gets worse in Q2 2027.
Why it matters: The closing will provide funds for general corporate purposes and working capital. This could support growth plans.
Supportive ifThe public offering closes on April 27, 2026, as planned.
Worry ifThe offering fails to close or is delayed beyond the expected date.
Why it matters: Earnings will show if Sonoma is improving cash flow and operating income. This is crucial for future growth.
Watch forThe Q2 earnings report shows positive cash flow from operations. This means they are getting closer to breakeven.
Also watch forThe Q2 earnings report shows worse cash flow. It also shows larger operating losses.
Why it matters: Improving cash flow is critical for funding operations and growth. It reflects financial health.
Supportive ifCash flow from operations turns positive in Q2 2027.
Worry ifCash flow from operations remains negative in Q2 2027.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$182 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $685 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,865 loss on $10,000 · 78.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.